Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism

Figure 1 Prostaglandin F_2α synthase is upregulation in patients with colorectal cancer. A: Prostaglandin F_2α synthase (PGFS) protein expression was verified using western blot in 37 pairs of colorectal cancer (CRC) and adjacent normal tissues; B: Real-time polymerase chain reaction analysis of PGFS mRNA expression in 37 pairs of CRC and adjacent normal tissues; C: Hematoxylin and eosin staining and immunohistochemistry for PGFS expression (scale bar, 50 μm); D: PGFS expression in non-response and response patients analyzed by the Cancer Treatment Response gene signature DataBase (http://ctrdb.ncpsb.org.cn/). ^aP < 0.05, ^bP < 0.01. T: Tumor; N: Adjacent normal tissues; PGFS: Prostaglandin F_2α synthase; HE: Hematoxylin and eosin.